PTC Therapeutics
✦ Quant Ownership Signal how this is computed
- The number of reporting institutions increased by 1 in the most recent period (2026/Q3).
- Total institutional ownership rose 1.6 percentage points.
Ownership vs. money flow
DivergingInstitutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 124.86% +1.65pp
- Institutions
- 473 +1
- As of
- 2026/Q3 vs. prior period
Holder types
Top holders as of 2026-09-30
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 7 buys · 40 sells
| Name | Role | Stake |
|---|---|---|
| Michael Schmertzler | Independent Chairperson | 1.74% |
| Matthew Klein | Chief Executive Officer | 0.19% |
| Mark Boulding | Chief Legal Officer | 0.13% |
| Christine Utter | Senior VP, Chief Accounting Officer & Head of People Services | 0.05% |
| Pierre Gravier | Chief Financial Officer | 0.04% |
| Lee Golden | Chief Medical Officer | 0.04% |
| Eric Pauwels | Chief Business Officer | 0.03% |
| Hege Sollie-Zetlmayer | Director | 0.02% |
| Glenn Steele | Independent Director | 0.02% |
| Mary Smith | Independent Director | 0.02% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-10-13 | Michael Schmertzler | Independent Chairperson | Automatic Disposition | -2,500 | $59.52–60.14 |
| 2026-10-08 | Mark Boulding | Chief Legal Officer | Derivative Exercise and Sale | -192 | $39.42–64.26 |
| 2026-10-06 | Michael Schmertzler | Independent Chairperson | Automatic Disposition | -2,500 | $63.38–63.95 |
| 2026-10-05 | Mark Boulding | Chief Legal Officer | Derivative Exercise and Sale | -2,073 | $39.42–64.16 |
| 2026-10-05 | Mark Boulding | Chief Legal Officer | Intent to Sell (Form 144) | -435 | $64.16 |
| 2026-10-04 | Mark Boulding | Chief Legal Officer | Intent to Sell (Form 144) | -1,638 | $64.03 |
| 2026-09-29 | Glenn Steele | Independent Director | Derivative Exercise and Sale | -12,000 | $11.23–65.16 |
| 2026-09-16 | Michael Schmertzler | Independent Chairperson | Automatic Disposition | -20,000 | $66.58–68.45 |
| 2026-09-09 | Michael Schmertzler | Independent Chairperson | Automatic Disposition | -20,000 | $67.34–68.67 |
| 2026-08-26 | Michael Schmertzler | Independent Chairperson | Automatic Disposition | -25,000 | $71.55–73.18 |
| 2026-08-19 | Michael Schmertzler | Independent Chairperson | Automatic Disposition | -25,000 | $70.78–73.67 |
| 2026-08-18 | Michael Schmertzler | Independent Chairperson | Intent to Sell (Form 144) | -50,000 | -- |
| 2026-08-16 | Mark Boulding | Chief Legal Officer | Derivative Exercise and Sale | -2,813 | $25.69–72.90 |
| 2026-08-03 | Matthew Klein | Chief Executive Officer | Open Market Disposition | -10,292 | $68.57 |
| 2026-07-27 | Hege Sollie-Zetlmayer | Director | Other Acquisition | +6,000 | -- |
| 2026-07-27 | Hege Sollie-Zetlmayer | Director | Other Derivative Acquisition | +5,213 | $75.39 |
| 2026-07-27 | Hege Sollie-Zetlmayer | Director | Initial Statement of Beneficial | 0 | -- |
| 2026-07-13 | Pierre Gravier | Chief Financial Officer | Open Market Disposition | -3,494 | $80.35 |
| 2026-07-08 | Neil Almstead | Chief Technical Operations Officer | Derivative Exercise and Sale | -2,464 | $46.54–90.25 |
| 2026-07-08 | Mary Smith | Independent Director | Derivative Exercise and Sale | -15,834 | $42.95–90.00 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.
PTC Therapeutics discussion 0 comments